Published in Exp Clin Psychopharmacol on May 01, 2006
Modest opioid withdrawal suppression efficacy of oral tramadol in humans. Psychopharmacology (Berl) (2007) 1.06
Discriminative stimulus effects of tramadol in humans. J Pharmacol Exp Ther (2011) 0.97
Endogenous opiates and behavior: 2006. Peptides (2007) 0.92
Physical dependence potential of daily tramadol dosing in humans. Psychopharmacology (Berl) (2010) 0.90
Effects of repeated tramadol and morphine administration on psychomotor and cognitive performance in opioid-dependent volunteers. Drug Alcohol Depend (2010) 0.87
Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment. Psychopharmacology (Berl) (2012) 0.85
Abuse liability and reinforcing efficacy of oral tramadol in humans. Drug Alcohol Depend (2012) 0.83
Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. Br J Clin Pharmacol (2012) 0.76
Caffeinated energy drinks--a growing problem. Drug Alcohol Depend (2008) 4.98
Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology (Berl) (2006) 4.23
Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction (2011) 3.42
Real-time electronic diary reports of cue exposure and mood in the hours before cocaine and heroin craving and use. Arch Gen Psychiatry (2009) 2.95
Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. Pain (2013) 2.58
Buprenorphine: how to use it right. Drug Alcohol Depend (2003) 2.35
Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction (2004) 2.11
QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med (2007) 2.07
Cognitive-behavioral therapy plus contingency management for cocaine use: findings during treatment and across 12-month follow-up. Psychol Addict Behav (2003) 1.94
Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain (2013) 1.89
A reinforcement-based therapeutic workplace for the treatment of drug abuse: three-year abstinence outcomes. Exp Clin Psychopharmacol (2002) 1.81
A randomized trial of long-term reinforcement of cocaine abstinence in methadone-maintained patients who inject drugs. J Consult Clin Psychol (2004) 1.76
Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend (2009) 1.56
Tobacco, cocaine, and heroin: Craving and use during daily life. Addict Behav (2009) 1.56
Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend (2003) 1.51
A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med (2013) 1.47
Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther (2004) 1.46
Incubation of cue-induced cigarette craving during abstinence in human smokers. Biol Psychiatry (2011) 1.44
The reinstatement model and relapse prevention: a clinical perspective. Psychopharmacology (Berl) (2003) 1.43
Methadone-related overdose deaths in rural Virginia: 1997 to 2003. J Addict Med (2013) 1.40
Prescriptions, nonmedical use, and emergency department visits involving prescription stimulants. J Clin Psychiatry (2016) 1.39
Behavioral contingencies improve counseling attendance in an adaptive treatment model. J Subst Abuse Treat (2004) 1.36
Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol Psychol (2006) 1.34
Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) (2007) 1.32
Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. Addict Behav (2005) 1.31
Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl) (2010) 1.31
Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend (2003) 1.30
Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend (2007) 1.28
Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction (2005) 1.25
Assessing the initiation of cocaine self-administration in humans during abstinence: effects of dose, alternative reinforcement, and priming. Psychopharmacology (Berl) (2003) 1.24
Characteristics of older opioid maintenance patients. J Subst Abuse Treat (2005) 1.22
Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. Drug Alcohol Depend (2011) 1.21
Daily life hour by hour, with and without cocaine: an ecological momentary assessment study. Psychopharmacology (Berl) (2010) 1.21
Decreased frontal white-matter volume in chronic substance abuse. Int J Neuropsychopharmacol (2005) 1.20
HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone. J Subst Abuse Treat (2006) 1.17
Changing profile of abused substances by older persons entering treatment. J Nerv Ment Dis (2008) 1.16
Individual and network factors associated with non-fatal overdose among rural Appalachian drug users. Drug Alcohol Depend (2010) 1.15
Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Exp Clin Psychopharmacol (2005) 1.14
Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry (2007) 1.14
The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. Drug Alcohol Depend (2011) 1.14
Choosing to take cocaine in the human laboratory: effects of cocaine dose, inter-choice interval, and magnitude of alternative reinforcement. Drug Alcohol Depend (2003) 1.13
Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users. Exp Clin Psychopharmacol (2012) 1.13
Are We There Yet? Feasibility of Continuous Stress Assessment via Wireless Physiological Sensors. ACM BCB (2015) 1.12
Clonidine blocks stress-induced craving in cocaine users. Psychopharmacology (Berl) (2011) 1.12
Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug Alcohol Depend (2008) 1.11
High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology (Berl) (2002) 1.09
Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend (2004) 1.09
Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. Addiction (2011) 1.09
Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug Alcohol Depend (2003) 1.08
Heroin and cocaine craving and use during treatment: measurement validation and potential relationships. J Subst Abuse Treat (2006) 1.08
Outpatient treatment entry and health care utilization after a combined medical/substance abuse intervention for hospitalized medical patients. J Gen Intern Med (2002) 1.08
An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction (2006) 1.08
Modest opioid withdrawal suppression efficacy of oral tramadol in humans. Psychopharmacology (Berl) (2007) 1.06
Randomized trial of prize-based reinforcement density for simultaneous abstinence from cocaine and heroin. J Consult Clin Psychol (2007) 1.06
The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction (2011) 1.06
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res (2012) 1.05
Brain mu-opioid receptor binding predicts treatment outcome in cocaine-abusing outpatients. Biol Psychiatry (2010) 1.05
The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am Heart J (2006) 1.01
Cigarette smoking knowledge, attitudes, and practices of patients and staff at a perinatal substance abuse treatment center. J Subst Abuse Treat (2010) 0.98
Service use and barriers to mental health care among adults with major depression and comorbid substance dependence. Psychiatr Serv (2013) 0.97
Voucher-based reinforcement of opiate abstinence during methadone detoxification. Drug Alcohol Depend (2002) 0.97
Discriminative stimulus effects of tramadol in humans. J Pharmacol Exp Ther (2011) 0.97
Marriage and relationship closeness as predictors of cocaine and heroin use. Addict Behav (2008) 0.96
Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. Psychopharmacology (Berl) (2006) 0.95
Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain (2012) 0.95
A dose response study of cognitive behavioral therapy in cocaine abusers. J Subst Abuse Treat (2002) 0.95
Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation. Psychopharmacology (Berl) (2008) 0.95
Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course. Drug Alcohol Depend (2011) 0.95
Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. J Subst Abuse Treat (2007) 0.94
Contingency management reduces injection-related HIV risk behaviors in heroin and cocaine using outpatients. Addict Behav (2007) 0.94
Repeated dosing with oral cocaine in humans: assessment of direct effects, withdrawal, and pharmacokinetics. Exp Clin Psychopharmacol (2009) 0.94
Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. Addiction (2003) 0.94
Cocaine abuse versus cocaine dependence: cocaine self-administration and pharmacodynamic response in the human laboratory. Drug Alcohol Depend (2009) 0.93
Treatment of patients with substance use disorders, second edition. American Psychiatic Association. Am J Psychiatry (2006) 0.93
Nonreporting of cannabis use: Predictors and relationship to treatment outcome in methadone maintained patients. Addict Behav (2006) 0.93
A randomized clinical trial of a Therapeutic Workplace for chronically unemployed, homeless, alcohol-dependent adults. Alcohol Alcohol (2011) 0.92
Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report. Drug Alcohol Depend (2009) 0.92
Monetary incentives to reinforce engagement and achievement in a job-skills training program for homeless, unemployed adults. J Appl Behav Anal (2013) 0.92